Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Analysis of Profitability Ratios 

Microsoft Excel

Profitability Ratios (Summary)

Cytokinetics Inc., profitability ratios

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Return on Sales
Operating profit margin -342.75% -264.54% -168.27% -367.97% -282.26%
Net profit margin -411.21% -305.72% -228.00% -452.93% -337.41%
Return on Investment
Return on equity (ROE) -88.29% -112.27% -409.84%
Return on assets (ROA) -38.33% -25.59% -23.85% -41.99% -50.33%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Cytokinetics Inc. operating profit margin ratio deteriorated from 2020 to 2021 and from 2021 to 2022.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Cytokinetics Inc. net profit margin ratio deteriorated from 2020 to 2021 and from 2021 to 2022.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Cytokinetics Inc. ROA deteriorated from 2020 to 2021 and from 2021 to 2022.

Operating Profit Margin

Cytokinetics Inc., operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Operating loss (324,202) (186,313) (93,943) (98,867) (88,916)
Revenues 94,588 70,428 55,828 26,868 31,501
Profitability Ratio
Operating profit margin1 -342.75% -264.54% -168.27% -367.97% -282.26%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 31.21% 31.89% 24.81% 39.03%
Amgen Inc. 38.57% 31.44% 37.70% 43.57%
Bristol-Myers Squibb Co. 17.96% 15.91% -21.60% 22.62%
Danaher Corp. 27.61% 25.35% 18.99% 18.25%
Eli Lilly & Co. 24.97% 22.45% 24.69% 22.29%
Gilead Sciences Inc. 27.17% 36.72% 16.72% 19.38%
Johnson & Johnson 24.63% 24.95% 23.60% 24.15%
Merck & Co. Inc. 30.27% 25.74% 16.47% 24.77%
Moderna Inc. 51.10% 75.22% -381.82%
Pfizer Inc. 34.83% 23.91% 19.47% 25.46%
Regeneron Pharmaceuticals Inc. 38.93% 55.67% 42.09% 28.10%
Thermo Fisher Scientific Inc. 18.69% 25.57% 24.19% 17.99%
Operating Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences 28.92% 28.39% 18.09% 25.68%
Operating Profit Margin, Industry
Health Care 13.52% 13.78% 10.30% 12.31%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Operating profit margin = 100 × Operating loss ÷ Revenues
= 100 × -324,202 ÷ 94,588 = -342.75%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Cytokinetics Inc. operating profit margin ratio deteriorated from 2020 to 2021 and from 2021 to 2022.

Net Profit Margin

Cytokinetics Inc., net profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Net loss (388,955) (215,314) (127,290) (121,692) (106,289)
Revenues 94,588 70,428 55,828 26,868 31,501
Profitability Ratio
Net profit margin1 -411.21% -305.72% -228.00% -452.93% -337.41%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 20.39% 20.54% 10.08% 23.69%
Amgen Inc. 26.42% 24.25% 29.97% 35.32%
Bristol-Myers Squibb Co. 13.71% 15.08% -21.20% 13.15%
Danaher Corp. 22.91% 21.84% 16.36% 16.80%
Eli Lilly & Co. 21.88% 19.71% 25.24% 37.27%
Gilead Sciences Inc. 17.02% 23.05% 0.51% 24.35%
Johnson & Johnson 18.90% 22.26% 17.82% 18.42%
Merck & Co. Inc. 24.49% 26.79% 14.72% 21.01%
Moderna Inc. 45.36% 69.04% -373.77%
Pfizer Inc. 31.27% 27.04% 22.95% 31.45%
Regeneron Pharmaceuticals Inc. 35.64% 50.25% 41.35% 26.91%
Thermo Fisher Scientific Inc. 15.47% 19.70% 19.79% 14.47%
Net Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences 23.12% 24.90% 13.44% 23.02%
Net Profit Margin, Industry
Health Care 10.55% 11.48% 7.64% 10.09%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Net profit margin = 100 × Net loss ÷ Revenues
= 100 × -388,955 ÷ 94,588 = -411.21%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Cytokinetics Inc. net profit margin ratio deteriorated from 2020 to 2021 and from 2021 to 2022.

Return on Equity (ROE)

Cytokinetics Inc., ROE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Net loss (388,955) (215,314) (127,290) (121,692) (106,289)
Stockholders’ equity (deficit) (107,900) 243,863 113,383 (10,937) 25,934
Profitability Ratio
ROE1 -88.29% -112.27% -409.84%
Benchmarks
ROE, Competitors2
AbbVie Inc. 68.60% 74.91% 35.30%
Amgen Inc. 178.97% 87.96% 77.20% 81.07%
Bristol-Myers Squibb Co. 20.37% 19.46% -23.84% 6.66%
Danaher Corp. 14.39% 14.24% 9.17% 9.94%
Eli Lilly & Co. 58.64% 62.16% 109.79% 319.09%
Gilead Sciences Inc. 21.62% 29.55% 0.68% 23.91%
Johnson & Johnson 23.36% 28.20% 23.25% 25.42%
Merck & Co. Inc. 31.57% 34.17% 27.91% 37.99%
Moderna Inc. 43.73% 86.26% -29.17% -43.75%
Pfizer Inc. 32.79% 28.47% 15.21% 25.77%
Regeneron Pharmaceuticals Inc. 19.14% 43.03% 31.86% 19.08%
Thermo Fisher Scientific Inc. 15.80% 18.94% 18.47% 12.45%
ROE, Sector
Pharmaceuticals, Biotechnology & Life Sciences 28.81% 31.93% 16.48% 27.56%
ROE, Industry
Health Care 22.88% 24.08% 15.82% 20.90%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
ROE = 100 × Net loss ÷ Stockholders’ equity (deficit)
= 100 × -388,955 ÷ -107,900 =

2 Click competitor name to see calculations.


Return on Assets (ROA)

Cytokinetics Inc., ROA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Net loss (388,955) (215,314) (127,290) (121,692) (106,289)
Total assets 1,014,775 841,319 533,803 289,814 211,178
Profitability Ratio
ROA1 -38.33% -25.59% -23.85% -41.99% -50.33%
Benchmarks
ROA, Competitors2
AbbVie Inc. 8.53% 7.88% 3.07% 8.84%
Amgen Inc. 10.06% 9.63% 11.54% 13.13%
Bristol-Myers Squibb Co. 6.53% 6.40% -7.61% 2.65%
Danaher Corp. 8.55% 7.73% 4.79% 4.85%
Eli Lilly & Co. 12.62% 11.44% 13.28% 21.17%
Gilead Sciences Inc. 7.27% 9.16% 0.18% 8.74%
Johnson & Johnson 9.57% 11.47% 8.41% 9.59%
Merck & Co. Inc. 13.30% 12.35% 7.72% 11.66%
Moderna Inc. 32.34% 49.46% -10.18% -32.34%
Pfizer Inc. 15.91% 12.11% 6.23% 9.72%
Regeneron Pharmaceuticals Inc. 14.85% 31.75% 20.47% 14.29%
Thermo Fisher Scientific Inc. 7.15% 8.12% 9.23% 6.33%
ROA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 11.04% 11.19% 5.14% 8.90%
ROA, Industry
Health Care 8.60% 8.69% 5.36% 7.15%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
ROA = 100 × Net loss ÷ Total assets
= 100 × -388,955 ÷ 1,014,775 = -38.33%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Cytokinetics Inc. ROA deteriorated from 2020 to 2021 and from 2021 to 2022.